Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients ≥65.

被引：1
|
作者：
Bordonaro, Roberto
Sobrero, Alberto F.
Frassineti, Luca
Ciuffreda, Libero
Aprile, Giuseppe
Thomas, Anne L.
Moore, Yan
Zilocchi, Chiara
Dochy, Emmanuelle
Taieb, Julien
Ferry, David Raymond
机构：
[1] Garibaldi Hosp Catania, Catania, Italy
[2] IRCCS Osped San Martino IST, Genoa, Italy
[3] IRCCS Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[4] Citta Salute & Sci Torino, Turin, Italy
[5] Univ Hosp Udine, Udine, Italy
[6] Univ Leicester, Leicester, Leics, England
[7] Sanofi Oncol, Cambridge, MA USA
[8] Sanofi, Milan, Italy
[9] Sanofi Oncol, Diegem, Belgium
[10] APHP, Paris, France
[11] Paris Descartes Univ, Paris, France
[12] New Cross Hosp, Wolverhampton, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
545
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety and effectiveness of aflibercept plus FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses
    Chau, I.
    Fakih, M. G.
    Garcia-Alfonso, P.
    Linke, Z.
    Ruiz-Casado, A.
    Polo Marques, E.
    Picard, P.
    Celanovic, M.
    Cartwright, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 227 - 227
  • [22] Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer
    Denda, Tadamichi
    Sakai, Daisuke
    Hamaguchi, Tetsuya
    Sugimoto, Naotoshi
    Ura, Takashi
    Yamazaki, Kentaro
    Fujii, Hirofumi
    Kajiwara, Takeshi
    Nakajima, Takako Eguchi
    Takahashi, Shin
    Otsu, Satoshi
    Komatsu, Yoshito
    Nagashima, Fumio
    Moriwaki, Toshikazu
    Esaki, Taito
    Sato, Takeo
    Itabashi, Michio
    Oki, Eiji
    Sasaki, Toru
    Sunaga, Yoshinori
    Ziti-Ljajic, Samira
    Brillac, Claire
    Yoshino, Takayuki
    CANCER SCIENCE, 2019, 110 (03) : 1032 - 1043
  • [23] Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI: Interim results of the non-interventional AIO study QoLiTrap
    Zahn, M.
    Scholten, F.
    von Moos, R.
    Thaler, J.
    Hofheinz, R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI - Interim results of the non-interventional AIO study QoLiTrap
    von Moos, R.
    Derigs, G.
    Scholten, F.
    Thaler, J.
    Losem, C.
    Kroening, H.
    Windemuth-Kieselbach, C.
    Hofheinz, R. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Final results from PRECEPT: efficacy and safety of second-line treatment with panitumumab and FOLFIRI in patients with metastatic colorectal cancer (mCRC)
    Cohn, A.
    Smith, D. A.
    Neubauer, M. A.
    Richards, D.
    Watkins, D. L.
    Zhang, K.
    Yassine, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 347 - 347
  • [26] Analysis of the quality of life in patients treated with Aflibercept and FOLFIRI for metastatic colorectal cancer (mCRC) - Interim results from the non-interventional QoLiTrap study
    Derigs, H. -G
    Scholten, F.
    Losem, C.
    Kroening, H.
    Windemuth-Kieselbach, C.
    Hofheinz, R. -D
    Oncology Research and Treatment, 2015, 38 : 61 - 62
  • [27] Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers
    Fernandez Montes, Ana
    Martinez Lago, Nieves
    Covela Rua, Marta
    de la Camara Gomez, Juan
    Gonzalez Villaroel, Paula
    Mendez Mendez, Jose Carlos
    Jorge Fernandez, Monica
    Salgado Fernandez, Mercedes
    Reboredo Lopez, Margarita
    Quintero Aldana, Guillermo
    Pelion Augusto, Maria Luz
    Grana Suarez, Begona
    Garcia Gomez, Jesus
    CANCER MEDICINE, 2019, 8 (03): : 882 - 889
  • [28] Safety and activity of ziv-aflibercept in combination with irinotecan, 5-fluorouracil, and lencovorin (FOLFIRI) no patients with colorectal cancer previously treated with irinotecan: Results from a phase 1 study
    Van Cutsem, Eric
    Khayat, David
    Verslype, Chris
    Billemont, Bertrand
    Tejpar, Sabine
    Merlc, Jean-Baptiste
    Bhargava, Pankaj
    Soussan-Lazard, Karen
    Assadourian, Sylvie
    Andria, Michael L.
    Le-Guennec, Solenn
    Rixe, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study
    Auvray, Marie
    Tougeron, David
    Auclin, Edouard
    Moulin, Valerie
    Artru, Pascal
    Hautefeuille, Vincent
    Hammel, Pascal
    Lecomte, Thierry
    Locher, Christophe
    Sickersen, Gaelle
    Coriat, Romain
    Lecaille, Cedric
    Vernerey, Dewi
    Taieb, Julien
    Pernot, Simon
    CLINICAL COLORECTAL CANCER, 2020, 19 (01) : 39 - +
  • [30] Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study
    Piringer, Gudrun
    Thaler, Josef
    Anchisi, Sandro
    Geffriaud-Ricouard, Christine
    Gueldner, Max
    Scholten, Felicitas
    Derigs, Hans-Guenter
    Bohanes, Pierre
    Gruenberger, Birgit
    Schwarz, Leonora
    von Moos, Roger
    Hofheinz, Ralf-Dieter
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (08)
12345